SG11201807832VA - Extended release conjugates of exenatide analogs - Google Patents
Extended release conjugates of exenatide analogsInfo
- Publication number
- SG11201807832VA SG11201807832VA SG11201807832VA SG11201807832VA SG11201807832VA SG 11201807832V A SG11201807832V A SG 11201807832VA SG 11201807832V A SG11201807832V A SG 11201807832VA SG 11201807832V A SG11201807832V A SG 11201807832VA SG 11201807832V A SG11201807832V A SG 11201807832VA
- Authority
- SG
- Singapore
- Prior art keywords
- suite
- prolynx
- blvd
- llc
- south
- Prior art date
Links
- 238000013265 extended release Methods 0.000 title abstract 3
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000002045 lasting effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662309330P | 2016-03-16 | 2016-03-16 | |
| US201662416058P | 2016-11-01 | 2016-11-01 | |
| PCT/US2017/022791 WO2017161174A1 (en) | 2016-03-16 | 2017-03-16 | Extended release conjugates of exenatide analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201807832VA true SG11201807832VA (en) | 2018-10-30 |
Family
ID=59852218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807832VA SG11201807832VA (en) | 2016-03-16 | 2017-03-16 | Extended release conjugates of exenatide analogs |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200164083A1 (https=) |
| EP (2) | EP3429608A4 (https=) |
| JP (1) | JP7017248B2 (https=) |
| KR (1) | KR20180129825A (https=) |
| CN (1) | CN109414469A (https=) |
| AU (2) | AU2017234680A1 (https=) |
| BR (1) | BR112018068639A2 (https=) |
| CA (1) | CA3016814A1 (https=) |
| MX (1) | MX2018011149A (https=) |
| RU (1) | RU2764547C2 (https=) |
| SG (1) | SG11201807832VA (https=) |
| WO (1) | WO2017161174A1 (https=) |
| ZA (2) | ZA201805953B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10745456B2 (en) * | 2015-04-01 | 2020-08-18 | The Scripps Research Institute | Methods and compositions related to GPCR agonist polypeptides |
| JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
| TW202027794A (zh) | 2018-10-03 | 2020-08-01 | 瑞士商諾華公司 | 血管生成素樣３多肽之持續遞送 |
| CN119970617A (zh) | 2019-04-05 | 2025-05-13 | 普罗林科斯有限责任公司 | 改良偶联接头 |
| MX2022001528A (es) * | 2019-08-07 | 2022-03-11 | Prolynx Llc | Esterilizacion con vapor de hidrogeles reticulados por enlazadores beta-eliminativos. |
| WO2022115563A1 (en) * | 2020-11-25 | 2022-06-02 | Prolynx Llc | Extended release hydrogel conjugates of c-natriuretic peptides |
| AU2022205377A1 (en) | 2021-01-08 | 2023-07-20 | Cellanome, Inc. | Devices and methods for analyzing biological samples |
| US12576400B2 (en) | 2021-01-08 | 2026-03-17 | Cellanome, Inc. | Methods for incubating and analyzing a cell in a compartment of a fluidic device |
| WO2025128916A1 (en) * | 2023-12-13 | 2025-06-19 | Cellanome, Inc. | Devices and methods for analyzing biological samples |
| KR102716759B1 (ko) | 2023-12-20 | 2024-10-15 | (주)인벤티지랩 | 엑세나타이드를 포함하는 서방형 주사제 조성물 및 이의 제조 방법 |
| WO2026020143A1 (en) * | 2024-07-19 | 2026-01-22 | Prolynx Llc | Extended-release conjugates of lipidated peptides, and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2278589T3 (es) * | 1999-01-14 | 2007-08-16 | Amylin Pharmaceuticals, Inc. | Excendinas destinadas a la inhibicion de glucagon. |
| JP2006501820A (ja) * | 2002-09-06 | 2006-01-19 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法 |
| BR0314996A (pt) * | 2002-10-02 | 2005-08-09 | Zealand Pharma As | Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada |
| CN100540565C (zh) * | 2005-01-14 | 2009-09-16 | 无锡宏创医药科技有限公司 | 修饰的Exendins及其应用 |
| GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
| CN101125207B (zh) * | 2006-11-14 | 2012-09-05 | 上海华谊生物技术有限公司 | 带有聚乙二醇基团的艾塞丁或其类似物及其制剂和用途 |
| WO2008116294A1 (en) * | 2007-03-23 | 2008-10-02 | Matregen Corp. | Exendin analogs |
| ES2672526T3 (es) | 2008-06-26 | 2018-06-14 | Prolynx Llc | Profármacos y conjugados de fármaco-macromolécula que presentan velocidades de liberación de fármaco controladas |
| WO2010017215A2 (en) * | 2008-08-04 | 2010-02-11 | The Regents Of The University Of California | Biodegradable microspheres and methods of use thereof |
| PT3345593T (pt) * | 2009-11-13 | 2023-11-27 | Sanofi Aventis Deutschland | Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina |
| ES2584381T3 (es) | 2010-05-05 | 2016-09-27 | Prolynx Llc | Liberación controlada de compuestos activos desde conjugados macromoleculares |
| US8703907B2 (en) | 2010-05-05 | 2014-04-22 | Prolynx Llc | Controlled drug release from dendrimers |
| EP2566334B1 (en) * | 2010-05-05 | 2018-04-18 | Prolynx, LLC | Controlled drug release from solid supports |
| WO2011156407A2 (en) * | 2010-06-09 | 2011-12-15 | Amylin Pharmaceuticals, Inc. | Glp-1 receptor agonists to treat pancre-atitis |
| CA2848142C (en) | 2011-09-07 | 2021-05-18 | Prolynx Llc | Hydrogels with biodegradable crosslinking |
| US20140256626A1 (en) * | 2011-10-18 | 2014-09-11 | Prolynx Llc | Peg conjugates of exenatide |
-
2017
- 2017-03-16 KR KR1020187029780A patent/KR20180129825A/ko not_active Abandoned
- 2017-03-16 JP JP2018548652A patent/JP7017248B2/ja not_active Expired - Fee Related
- 2017-03-16 CA CA3016814A patent/CA3016814A1/en active Pending
- 2017-03-16 EP EP17767565.9A patent/EP3429608A4/en not_active Withdrawn
- 2017-03-16 RU RU2018136200A patent/RU2764547C2/ru active
- 2017-03-16 AU AU2017234680A patent/AU2017234680A1/en not_active Abandoned
- 2017-03-16 SG SG11201807832VA patent/SG11201807832VA/en unknown
- 2017-03-16 BR BR112018068639A patent/BR112018068639A2/pt not_active IP Right Cessation
- 2017-03-16 CN CN201780018057.6A patent/CN109414469A/zh active Pending
- 2017-03-16 EP EP21189671.7A patent/EP3922269A1/en not_active Withdrawn
- 2017-03-16 WO PCT/US2017/022791 patent/WO2017161174A1/en not_active Ceased
- 2017-03-16 US US16/085,139 patent/US20200164083A1/en not_active Abandoned
- 2017-03-16 MX MX2018011149A patent/MX2018011149A/es unknown
-
2018
- 2018-09-05 ZA ZA201805953A patent/ZA201805953B/en unknown
-
2019
- 2019-09-02 ZA ZA2019/05787A patent/ZA201905787B/en unknown
-
2021
- 2021-09-17 AU AU2021232810A patent/AU2021232810A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN109414469A (zh) | 2019-03-01 |
| ZA201905787B (en) | 2021-03-31 |
| AU2021232810A1 (en) | 2021-10-14 |
| RU2764547C2 (ru) | 2022-01-18 |
| AU2017234680A1 (en) | 2018-10-11 |
| AU2017234680A2 (en) | 2018-12-13 |
| MX2018011149A (es) | 2019-05-30 |
| CA3016814A1 (en) | 2017-09-21 |
| EP3429608A1 (en) | 2019-01-23 |
| EP3429608A4 (en) | 2019-12-11 |
| BR112018068639A2 (pt) | 2019-07-30 |
| WO2017161174A1 (en) | 2017-09-21 |
| RU2018136200A (ru) | 2020-04-16 |
| EP3922269A1 (en) | 2021-12-15 |
| JP7017248B2 (ja) | 2022-02-08 |
| RU2018136200A3 (https=) | 2020-12-25 |
| US20200164083A1 (en) | 2020-05-28 |
| ZA201805953B (en) | 2019-11-27 |
| KR20180129825A (ko) | 2018-12-05 |
| JP2019511497A (ja) | 2019-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201807832VA (en) | Extended release conjugates of exenatide analogs | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201908092RA (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
| SG11201909777YA (en) | Modulatory polynucleotides | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201901020RA (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11202000105QA (en) | Anti-cd166 antibodies and uses thereof | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201909868YA (en) | Compositions and methods of treating huntington's disease | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201909322VA (en) | Treatment of asthma with anti-tslp antibody | |
| SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201907420VA (en) | Inhibition of smarca2 for treatment of cancer | |
| SG11201906412SA (en) | Pyridine compounds as allosteric shp2 inhibitors | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201806992VA (en) | Antibodies to tigit | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201809709UA (en) | Aerosol generating systems | |
| SG11201900038QA (en) | Compositions and methods comprising improvements of crispr guide rnas using the h1 promoter | |
| SG11201810801QA (en) | Brain delivery protein | |
| SG11201408174UA (en) | Antibody formulation |